Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Motor system

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    601 result(s) found for: Motor system. Displaying page 1 of 31.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-005367-32 Sponsor Protocol Number: PROMISE Start Date*: 2016-02-29
    Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
    Full Title: PROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN
    Medical condition: Amiotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10028003 Motor neurone disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004129-89 Sponsor Protocol Number: Motor-Neuromod_01, Part I-III Start Date*: 2005-09-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation
    Medical condition: Healthy volunteers Patients in the chronic stage (> 1 year) after stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004501-32 Sponsor Protocol Number: NL51240.018.14 Start Date*: 2014-12-11
    Sponsor Name:Academic Medical Center
    Full Title: Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment...
    Medical condition: Patients with advanced PD who's motor symptoms — severe response fluctuations, dyskinesias, painful dystonia and / or bradykinesia — cannot be controlled despite optimal oral pharmacological therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002827-14 Sponsor Protocol Number: TreatSPG11 Start Date*: 2021-01-19
    Sponsor Name:IRCCS Fondazione Stella Maris
    Full Title: Phase 2 pharmacological experimental study to test the safety of miglustat in subjects with hereditary spastic paraplegia type 11
    Medical condition: Spastic paraparesis type 11 (SPG11), caused by mutations in spatacsin protein, is characterized by the association of peripheral neuropathy, parkinsonism, ataxia, cognitive impairment, hypotrophy o...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019903 Hereditary spastic paraplegia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004297-34 Sponsor Protocol Number: 236252 Start Date*: 2018-03-31
    Sponsor Name:Aston University
    Full Title: A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001315-44 Sponsor Protocol Number: TAK-935-18-002(OV935) Start Date*: 2022-05-24
    Sponsor Name:Takeda Development Center America, Inc.
    Full Title: A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)
    Medical condition: Epileptic Encephalopathies: Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10073682 Dravet syndrome LLT
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    22.1 10010331 - Congenital, familial and genetic disorders 10083005 CDKL5 deficiency disorder PT
    23.0 10010331 - Congenital, familial and genetic disorders 10083952 Dup15q syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-004998-32 Sponsor Protocol Number: ARGX-117-2003 Start Date*: 2022-12-19
    Sponsor Name:argenx BV
    Full Title: A Long-Term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerabillity, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Mult...
    Medical condition: Multifocal Motor Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004175-73 Sponsor Protocol Number: HP-CD-CL-2002 Start Date*: 2017-09-27
    Sponsor Name:Herantis Pharma Plc
    Full Title: A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administere...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-000155-12 Sponsor Protocol Number: 2018_49 Start Date*: 2020-05-12
    Sponsor Name:InBrain Pharma SAS
    Full Title: A new concept of continuous dopaminergic stimulation by cerebroventricular administration of A-dopamine (dopamine stored in anaerobia) for severe motor fluctuations in Parkinson’s disease?
    Medical condition: Proof of concept study: prospective, monocentric, controlled randomized study according a cross over design with 2 groups: cerebroventricular administration of A-dopamine versus optimized oral trea...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-009868-31 Sponsor Protocol Number: 80-82310-98-09088 Start Date*: 2009-06-18
    Sponsor Name:ZonMW
    Full Title: Quality of life, gross motor function, and actual everyday physical activity level in children with spastic Cerebral Palsy: (cost)effectiveness of combined treatment with multilevel botulinum-toxin...
    Medical condition: Spastic Cerebral Palsy, GMFCS levels I-III
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000468-83 Sponsor Protocol Number: 31-10-273 Start Date*: 2011-12-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tourette’s Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000467-27 Sponsor Protocol Number: 31-10-272 Start Date*: 2011-11-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette's Disorder
    Medical condition: Tourette’s Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-000469-11 Sponsor Protocol Number: 31-10-274 Start Date*: 2011-12-15
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
    Medical condition: Tourette’s Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10044126 Tourette's disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) RO (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004424-15 Sponsor Protocol Number: NOE-TTS-211 Start Date*: Information not available in EudraCT
    Sponsor Name:Noema Pharma Australia Pty Ltd
    Full Title: An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult and adolescent male patients with To...
    Medical condition: Tourette Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10044127 Tourette's syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003140-83 Sponsor Protocol Number: NBI-921352-DEE2012 Start Date*: 2021-10-12
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developm...
    Medical condition: SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) PL (Completed) DE (Completed) BE (Completed) FR (Completed) NL (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000100-41 Sponsor Protocol Number: PN018 Start Date*: 2018-11-21
    Sponsor Name:Abide Therapeutics, Inc.
    Full Title: A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients with Tourette Syndrome or Chronic Motor Tic Disorder
    Medical condition: Tourette syndrome or chronic motor tic disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10044127 Tourette's syndrome LLT
    20.0 100000004873 10009005 Chronic motor tic disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003498-41 Sponsor Protocol Number: D-Fampr Start Date*: 2015-09-22
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of dalfampridine on mobility in the context of daily life
    Medical condition: Motor behaviour and cognition in multiple sclerosis patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004685-10 Sponsor Protocol Number: PD-1105 Start Date*: 2019-01-11
    Sponsor Name:Voyager Therapeutics, Inc.
    Full Title: A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor Fluctuatio...
    Medical condition: Patients with Parkinson's Disease with motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000755-97 Sponsor Protocol Number: EPFL-CNBI-2017-01 Start Date*: 2017-03-16
    Sponsor Name:Defitech Chair in Brain-Machine Interface, EPFL
    Full Title: Brain-computer interface and neuromuscular stimulation for rehabilitation following chronic stroke
    Medical condition: I61 - Intracerebral haemorrhage I63 - Cerebral infarction Chronic condition (at least 10 months after occurrence of cerebrovascular accident)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2012-001995-12 Sponsor Protocol Number: I10E-0901 Start Date*: 2015-05-19
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in ...
    Medical condition: Multifocal motor neuropathy (MMN)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10065579 Multifocal motor neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 17:46:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA